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ABSTRACT: In this paper a detailed analysis of thirty 4-aminoquinoline-based compounds with regard to their potential as an-
tileishmanial drugs has been carried out. Ten compounds demonstrated IC50<1 µM against promastigote stages of L. infantum and 
L. tropica, and five compounds showed IC50<1 µM against intramacrophage L. infantum amastigotes. Two compounds showed 
dose-dependent enhancement of NO and ROS production by bone marrow-derived macrophages and remarkable reduction of para-
site load in vivo, with advantage of being short-term and orally active. To the best of our knowledge, this is the first example of 4-
amino-7-chloroquinoline derivatives active in Leishmania infantum infected mice. 
Leishmaniasis is a neglected parasitic disease transmitted by 
more than 90 sand fly species. The disease may occur in hu-
mans and animals, including dogs and rodents. Human infec-
tion is caused by about 21 of the 30 species of Leishmania 
parasites that infect mammals.1,2 Currently, 2 million people 
are infected every year and more than 350 million people are 
at risk mostly in tropical and subtropical areas.3 The life cycle 
of Leishmania parasite includes sand fly and vertebrate host 
stages. After an infected sand fly deposits metacyclic pro-
mastigotes into the host’s skin during blood feeding, they are 
phagocytized by macrophages and then transformed into 
aflagellated amastigotes. In macrophages, amastigotes multi-
ply and after being released they infect new macrophages. The 
sand fly ingests infected macrophages during a blood meal and 
the life cycle continues within the sand fly gut.2 Treatment of 
leishmaniasis varies and adapts to the severity of the disease 
and species of the parasite.1 Antileishmanial drugs that are 
presently in use are pentavalent antimonials, amphotericin B, 
pentamidine, miltefosine and others, with AmBisome® and 
sodium stibogluconate – paromomycin combination therapy 
being the first choice for fighting leishmania infection (Chart 
1).3,4 All current therapies present serious side effects, includ-
ing toxicity, and for some of them resistance development are 
emerging.5 In addition, the vaccine for preventing human 
leishmaniasis, which could have an immense influence on 
suppression of the disease, is still not available.6 Thus, the de-
velopment of potent small molecule inhibitors of Leishmania 
parasites and clinical trials of new drugs are the priorities 
(DNDI-0690, Chart 1).4,7  
 
Chart 1. Examples of current antileishmanial medicines and 
new potent drug candidate. 
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Beside their antimalarial activity, derivatives of 4-
aminoquinoline also demonstrated antibacterial, antifungal, 
antitumor and antileishmanial activity.8 4-Amino-7-
chloroquinoline analogues and their Pt(II) complexes were 
shown to be active against promastigotes of different Leish-
mania species.8 Another study investigated the in vitro activity 
of a series of 4-amino-7-chloroquinolines conjugated to sul-
fonamide, hydrazide and hydrazine against L. amazonensis 
promastigotes and amastigotes, revealing the ability of these 
Page 1 of 6
ACS Paragon Plus Environment
ACS Medicinal Chemistry Letters
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 compounds to induce depolarization of the mitochondrial 
membrane potential in promastigotes and infected macrophag-
es in vitro.9,10 Steroid linked aminoquinolines also proved to 
have significant activity against both promastigote and 
amastigote forms of L. major in vitro.11 
Here we report on the synthesis and antileishmanial poten-
tial of novel 4-aminoquinoline derivatives and some amino-
quinoline-based drugs previously published by our group 
(Chart 2).12-16 
 
Chart 2. Structures of examined compounds 
NCl
X
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R
N()n NZ
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R
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X
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5: X=NO2; Y=Cl; R,R1=H; Z=CH2; n=1
6: X=NH2; Y=Cl; R,R1=H; Z=CH2; n=1
7: X=H; Y=Cl; R,R1=H; Z=(CH2)3; n=2
8: X=H; Y=Cl; R,R1=Me; Z=CH2; n=2
9: X=H; Y=H; R=Me; R1=H; Z=CH2; n=2
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15: X1=F; X2=H, Y=Cl, R=H, Z=                    ; n=2
16: X1=F; X2=H, Y=H, R=H, Z=                     ; n=2
17: X1=F; X2=H, Y=Cl, R=H, Z=                     ; n=3
18: X1=F; X2=H, Y=H, R=H, Z=                     ; n=3
19: X1=F; X2=H, Y=Cl, R=Me, Z=                     ; n=3
20: X1=CN; X2=H, Y=H, R=Me, Z=                     ; n=3
21: X1=F; X2=H, Y=H, R=H, Z=                  ; n=3
 
 
 
 
 
 
 
 
 
The introduction of different substituents at C(3) of quino-
line moiety was of interest since it is expected to influence the 
electronic density to substantial extent. Sontochin-like com-
pounds, as well as our previously published aminoquinoline 
derivatives with fluorine atom at the same position proved to 
be of significant antiplasmodial potential.12 Here, we explore 
the effect of nitro and amino substituents on antileishmanial 
activity (Scheme 1). Nitro substituent in 3112 enabled nucleo-
philic substitution under mild conditions,17 resulting in com-
pounds 1 and 2 in reasonably good yield. Reduction of nitro 
group to amino using tin(II)-chloride12 afforded compounds 3 
and 4. 
 
Scheme 1. Synthesis of substituted chloroquine-like com-
pounds 1-4 
NCl
Cl
NO2
31
i)
1: R=H, n=1 (78%)
2: R=Me, n=2 (78%)
3: R=H, n=1 (40%)
4: R=Me, n=2 (60%)
NCl
NH
NH2
R
N()n
NCl
NH
NO2
R
N()n
i) amine, Et3N, CH2Cl2, 0 °C to reflux; ii) SnCl2, EtOH
ii)
 
Aminoquinolines with adamantane carrier were synthesized 
as presented in Scheme 2. Commercially available 1-
adamantanemethanol was transformed into mono-Boc protect-
ed amine 32 in moderate yield using procedure we established 
earlier.12 Removal of protecting group under standard condi-
tions gave amine 33 in good yield. Dichloride 31 was submit-
ted to nucleophilic substitution with amine 33 affording ami-
noquinoline 5 in good yield. Nitro group in 5 was further re-
duced to amine 6 using SnCl2. 
Compound 10 with piperazine moiety in linker was synthe-
sized in several reaction steps, starting from commercially 
available 3,3'-piperazine-1,4-diyldipropan-1-amine 34 
(Scheme 3). After protection of amino groups and nucleophilic 
substitution with 4,7-dichloroquinoline, compound 36 was ob-
tained in moderate yield. Removal of protecting group under 
standard conditions gave amine 37 in high yield. Reductive 
amination of the obtained amine with adamantane-1-
acetaldehyde furnished the compound 38. Compound 10 was 
obtained as HCl salt of amine 38 (confirmed by elemental 
analysis). 
 
Scheme 2. Synthesis of adamantane derivatives 5 and 6 
OH NHNH
N
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X
5: X=NO2 (72%)
6: X=NH2 (71%)
i) iii)
i) 1) PCC, DCM, 2) tert-butyl (3-aminopropyl)carbamate, MeOH/DCM, AcOHglac, 3) NaBH4; 
ii) TFA, DCM; iii) 31, DCM, 0 °C to reflux; iv) SnCl2, EtOH 
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Scheme 3. Synthesis of compound 10 
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1:10), r.t., 24 h; 2,5 M NaOH; iv) aldehyde, NaBH(OAc)3, DCM, r.t., 24 h; v) MeOH/HCl
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37: R=H (89%)             
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10: 4HCl (85%)                   
                
iv)
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Benzothiophene derivative 15 was obtained by reductive 
amination starting from aldehyde 3913 in good yield. Com-
pound 21 was obtained in rather low yield by Sonogashira 
coupling reaction of 4013 and N-(prop-2-yn-1-yl)-N'-(quinolin-
4-yl)butane-1,4-diamine 41. (Scheme 4). 
 
Scheme 4. Synthesis of novel benzothiophene derivatives 15 
and 21 
40
S
F
N
H
NH
N
21: 27%
S
Br
F
S
F CHO
39
i)
S
F NH
NH
N
Cl
15: 71%
i) 1) AQ3, AcOHglac, MeOH/DCM, 2) NaBH4; ii) 41, PdCl2(PPh3)2, PPh3, CuI, Et2NH, 
DMF, MW, 120  oC, 25 min 
ii)
 
Reduction of quinoline core was designed in order to ex-
plore the effect of resulting deviation from planarity on inhibi-
tion of Leishmania proliferation (Scheme 5). Compound 42, 
synthesized according to the procedure described in litera-
ture,18 was transformed into 43 in acceptable yield. Selective 
reduction of benzene core of quinoline and hydrogenolysis of 
chlorine were performed by hydrogenation method using plat-
inum(IV) oxide in acetic acid as solvent in the presence of 
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 perchloric acid. Deacetylation of compound 43 in 2M HCl 
gave compound 44 in high yield. Using Sandmeyer reaction 
conditions (NaNO2, AcOH, HCl; CuCl), compound 44 was 
transformed into 45. 
 
Scheme 5. Synthesis of tetrahydroquinoline core 
N
NH
Cl
O
42
N
NH
O
43: 65%
i)
N
X
44: X=NH2 (89%)
45: X=
 
Cl (53%)
i) PtO2, H2, AcOH, HClO4, ii) 2M HCl, 70 °C; iii) 1) AcOHglac, 28% HCl, 
NaNO2aq, 0 °C, 2) CuCl, 28% HCl, 0 °C to r.t.
ii)
iii)
 
Syntheses of thiophene-based tetrahydroquinoline com-
pounds are presented on Scheme 6. Compound 45 was submit-
ted to Buchwald-Hartwig amination affording the amines 22, 
23 and 46 in low to moderate yield. Compound 46 with eight 
methylene groups in linker was subjected to reductive amina-
tion with 4-[5-(4-formylphenyl)thiophen-2-yl]benzonitrile13 to 
obtain 24. Methylation of secondary nitrogen using 37% for-
maldehyde gave compound 25 in high yield.  
 
Scheme 6. Synthesis of compounds 22-25  
N
Cl
45
N
NH
R
N
R1
R1()n
22: n=1, R=H, R1=Et (43%)
23: n=2, R=Me, R1=Et (27%)
46: n=6, R, R1=H (66%)
i) ii)
N
NH
N
S CNR
()7
24: R=H (32%)
25: R=Me (84%) iii)
i) amine, Pd(OAc)2, SPhos, K3PO4, dioxane, 85 °C, 24h; ii) for compound 46: 
1) 4-[5-(4-formylphenyl)thiophen-2-yl]benzonitrile, AcOHglac, MeOH/DCM, 2) NaBH4; iii) 37% 
HCHO, ZnCl2, NaBH3CN, MeOH
 
The syntheses of other compounds are presented in our pre-
vious papers.12-16 Full details of synthetic procedures, NMR 
spectra and HPLC purities are given in the Supporting Infor-
mation. 
Thirty compounds presented on Chart 2 were first examined 
for their activity against L. infantum and L. tropica pro-
mastigote stage using standard MTT assay (Table 1, Table 
S1). Ten compounds showed IC50 values of the same order of 
magnitude as amphotericin B (IC50 < 1 µM), which was used 
as a positive control. C(3)-substituted chloroquine-like com-
pounds (1-4) displayed poor antileishmanial activity against 
both promastigote species. However, hybrids of such com-
pounds with adamantane carrier resulted in more active de-
rivatives 5 and 6. Among adamantane derivatives without sub-
stituent at C(3), compound 7 showed clear improvement of 
potency. The most potent compound was 10, with piperazine 
moiety in linker. 
Benzothiophene compounds 15 and 17 with chlorine atom 
at C(7) position of quinoline moiety were more potent than 
their des-chloro analogues 16 and 18, suggesting that chlorine 
atom would be important for the activity. Replacing phenyl 
group with C≡C bond did not produce any significant effect on 
the activity (18 vs 21). 
While chloroquine-like compounds, tetrahydroquinolines 22 
and 23 were completely inactive, hybrids with thiophene car-
rier 24 and 25 showed >100-fold increase in activity. Among 
other thiophenes, compound 29 with eight methylene groups 
between two nitrogens, demonstrated the highest potency 
against both Leishmania promastigote species. All compounds 
were also checked for cytotoxicity against differentiated THP-
1 cells. For both species moderate selectivity indices were ob-
tained (SITHP-1/L.i.=1.3-9.9; SITHP-1/L.t.=1.1-10.9, Table 1).   
 
Table 1. In vitro activities against L. infantum and L. tropica 
promastigotes and cytotoxicity against THP-1 human cellsa 
Comp. 
L.  
infantum 
IC50 (µM)b 
L. 
 tropica 
IC50 (µM)b 
THP-1 
IC50 (µM)c 
SI 
(THP/  
L.i.)d 
SI 
(THP/ 
L.t.)d 
1 8.67 2.77 23.66 2.7 8.5 
2 6.49 2.96 >109.6 >16.9 >37.0 
3 16.60 9.35 >65.2 >3.9 >7.0 
4 16.60 6.63 >59.7 >3.6 >9.0 
5 1.91 2.24 12.59 6.6 5.6 
6 1.77 1.30 6.39 3.6 4.9 
7 0.73 0.66 1.81 2.5 2.7 
8 2.46 1.84 3.29 1.3 1.8 
9 2.40 2.35 4.90 2.0 2.1 
10 0.52 0.51 1.00 1.9 2.0 
11 1.14 1.31 2.96 2.6 2.3 
12 0.64 0.68 3.76 5.8 5.5 
13 1.23 1.24 4.25 3.4 3.4 
14 0.51 0.50 1.91 3.8 3.8 
15 0.48 0.43 4.73 9.9 10.9 
16 1.03 0.81 2.31 2.2 2.8 
17 1.02 0.85 4.28 4.2 5.0 
18 1.24 1.02 2.35 1.9 2.3 
19 0.98 0.91 2.44 2.5 2.7 
20 1.55 1.22 2.79 1.8 2.3 
21 1.02 1.37 7.11 7.0 5.2 
22 >76.5 >76.5 >76.5 >1 >1 
23 >69.1 >69.1 >69.1 >1 >1 
24 0.72 0.75 2.31 3.2 3.1 
25 0.83 0.80 3.68 4.4 4.6 
26 2.30 1.94 5.01 2.2 2.6 
27 1.22 1.54 2.80 2.3 1.8 
28 5.42 7.11 8.10 1.5 1.1 
29 0.35 0.30 1.38 4.0 4.6 
30 0.80 1.06 3.85 4.8 3.6 
Controle 0.13 0.14 >10.8 >83.1 >77.1 
aAntileishmanial IC50 values against promastigote stages (µM), MTT assay; bAll in vitro experiments were 
performed in duplicate, mean values are given; cCytotoxicity against differentiated THP-1, hu-
man monocytic cell line derived from an acute monocytic leukemia patient. dSelectivity index; eControl drug: 
amphotericin B
 
 
All compounds were tested against intramacrophage 
amastigotes of L. infantum at 0.5 µM, non-toxic concentration 
on human cells (Table S2). Compounds that showed more than 
25% inhibition were tested in dose-response experiments and 
IC50 were calculated. Five compounds showed IC50 less than 1 
µM. Among them, compounds 10, 15 and 18 were the most 
active, while compound 15 was the least toxic with good se-
lectivity index (Table 2).  
Three compounds with good antileishmanial potential (10, 
15 and 18) were subjected to in vivo tolerability evaluation in 
a mice model. All compounds were tested orally at 300 mg/kg 
(single dose) as suspension in 0.1%Tween/0.5% HEC in wa-
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 ter. Compound 15 was also tested at lower 50 mg/kg dose by 
subcutaneous route of administration (in sunflower oil). Com-
pound 18 showed toxic effects when given orally with 3/5 
mice alive at the end of experiment, while compounds 10 and 
15 given either p.o. or s.c. proved to be tolerable, since all 
mice survived 30 days after administration and showed normal 
appearance and behavior.  
 
Table 2. In vitro activities against intramacrophage L. infan-
tum amastigotes 
Comp. 
In Vitro 
Antiamastigote 
Activity  
at 0.5 µMa 
In Vitro 
Antiamastigote 
Activity  
IC50 (µM)b 
THP-1c 
IC50 (µM) 
SI 
(THP/IPT)d 
8 29.6 1.91 3.29 1.72 
10 72.2 0.31 1.00 3.22 
11 26.4 1.85 2.96 1.60 
13 38.9 1.29 4.25 3.29 
14 26.4 >1 1.91 <1.91 
15 47.6 0.58 4.73 8.15 
18 42.7 0.65 2.35 3.61 
19 36.9 0.73 2.44 3.34 
20 42.2 0.79 2.79 3.51 
24 29.6 >1 2.31 <2.31 
Controle 95.5 0.21 >10.8 >51.4 
aMean value of two or three experiments. bMean value of two experiments. cCytotoxicity against differentiated 
THP-1, human monocytic cell line derived from an acute monocytic leukemia patient. dSelectivity Index (IC50 
against THP-1/IC50 against intracellular amastigotes); eControl drug: amphotericin B. 
 
Compounds 10 and 15 were further evaluated for reduction 
of liver parasite load in a mouse model of visceral leishmania-
sis (Balb/c mice infected intravenously with L. infantum 
amastigotes). Results presented in Figure 1 are given as % of 
reduction relative to control (untreated infected mice, Table 
S3, Table S4). Compound 15 was tested per os at two different 
doses 50 mg/kg × 4 days and 100 mg/kg × 4 days and showed 
significant reduction of parasites in the liver, 95% and 99%, 
respectively. Compound 10 was also tested per os at 60 mg/kg 
× 4 days and 100 mg/kg × 4 days. At lower applied dose it re-
duced parasite load 96% compared to control. Although at 
higher dose complete clearance was achieved, it showed signs 
of toxicity, since 1 mouse died on day 10 and 1 mouse died on 
day 12. Both compounds were also subjected to s.c. admin-
istration at lower doses (Figure 1). Compound 10 administered 
at dose 10 mg/kg × 4 days reduced parasite load by 81%. At 
5 mg/kg × 5 days and lower both compounds exhibited poorer 
activities (57% and 18-48% for 10 and 15, respectively). 
However, these results are extremely important, giving us the 
essential information about dose-dependent behavior of select-
ed 4-aminoquinolines.    
In order to investigate the putative mechanism of action 
(MOA),9 we examined the production of nitric oxide and ROS 
by IFNγ primed murine bone marrow-derived macrophages 
(BMDM) treated with 10 or 15. Experiments were performed 
at several concentrations not toxic on BMDM. Not toxic con-
centrations were determined by MTT assay (data not shown). 
The concentration of nitrite and ROS was determined using 
Griess reagent and H2DCFDA, respectively. Results revealed 
that compounds 10 and 15 increased the production of nitric 
oxide by IFNγ-primed macrophages only at the highest dose 
used (Figure S1). Both compounds induced persistent increase 
of ROS at all the doses tested (Figure S2). 
 
Figure 1. Reduction of parasite load in a mouse model by com-
pounds 10 and 15 
 
Currently, several noteworthy in vivo studies have been 
published,19,20,21 Nitroimidazo-oxazole compound DNDI-VL-
2098 previously identified as a favorable candidate did not 
proceed to the clinical study.20,22 However, its oxazine deriva-
tive DNDI-0690 was very recently recognized as a new prom-
ising candidate for Phase I trial for VL.4,7 In the last ten years, 
only a few 4-amino- and 2-alkenylquinolines with modest ac-
tivity against Leishmania parasites in vivo were also identi-
fied.23-25 8-Aminoquinoline derivative sitamaquine appeared to 
be orally active against visceral leishmaniasis and is presently 
under clinical investigation.26 
Here, we identified two 4-amino-7-chloroquinoline com-
pounds bearing benzothiophene or adamantane moieties as 
potent antileishmanial candidates with significant in vivo effi-
cacy. The importance of this work lies in discovery of highly 
active short-term compounds, tolerable in mice, being the first 
example of a 4-amino-7-chloroquinoline active in L. infantum 
mice model of visceral leishmaniasis. Although a certain dose-
dependent enhancement of NO and ROS production (which 
can contribute to the amastigotes killing) was observed in the 
presence of 10 and 15, MOA still remains unclear. Further 
studies will be focused on discovering specific target in order 
to elucidate the mechanism of action. Based on compounds’ 
tolerability in mice model and noteworthy in vivo activity, fu-
ture efforts will be focused on improvement of pharmacokinet-
ic profile and enhancement of the antileishmanial activity. 
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The Supporting Information is available free of charge on the 
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Full details of synthetic procedures, biological assays, procedures 
for the determination of the HPLC purity, in vitro activities on 
promastigote stages (Table S1), in vitro activities against intra-
macrophages L. infantum amastigotes (Table S2), in vivo an-
tileishmanial activity (Table S3, Table S4), nitric oxide and ROS 
production (Figure S1, Figure S2) (Supporting information – I, 
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NMR spectra and HPLC purity spectra of all tested compounds 
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